Cosmos Pharmaceutical (3349.T) Stock Price

Cosmos Pharmaceutical Price

JPX·CLOSED
6,413.00JPY-41.00 (-0.64 %)
Market closed

Over the last 19 years Cosmos Pharmaceutical grew revenue by 12.7% annually, reaching 1.01 T JPY. Earnings per share have grown at 7.3% per year over the last 19 years. For Cosmos Pharmaceutical, the net margin of 3.1% is broadly stable versus 3.7% a few years ago. At today's price the dividend yield works out to roughly 1.09%. The payout ratio is around 19% of earnings. The dividend has grown at 10.8% per year over the past 19 years. The consensus 12-month price target for Cosmos Pharmaceutical is 9,945.00 JPY, about 55.1% above where the stock trades today. Of 18 analysts, 12 rate the stock a buy — an overall Buy consensus. The stock trades about 12% above its 52-week low.

Cosmos Pharmaceutical stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Cosmos Pharmaceutical over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Cosmos Pharmaceutical stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Cosmos Pharmaceutical's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Cosmos Pharmaceutical Stock Price History
DateCosmos Pharmaceutical Price
8/12/20266,413.00 JPY
8/10/20266,454.00 JPY
8/7/20266,455.00 JPY
8/6/20266,318.00 JPY
8/5/20266,263.00 JPY
8/4/20266,311.00 JPY
8/3/20266,351.00 JPY
7/31/20266,474.00 JPY
7/30/20266,880.00 JPY
7/29/20266,863.00 JPY
7/28/20266,612.00 JPY
7/27/20266,334.00 JPY
7/24/20266,236.00 JPY
7/23/20266,203.00 JPY
7/22/20266,181.00 JPY
7/21/20266,333.00 JPY
7/17/20266,448.00 JPY
7/16/20266,307.00 JPY
7/15/20266,252.00 JPY
7/14/20266,516.00 JPY
7/13/20266,416.00 JPY
7/10/20266,327.00 JPY
7/9/20266,506.00 JPY
7/8/20266,612.00 JPY
7/7/20266,747.00 JPY
7/6/20266,650.00 JPY
7/3/20266,505.00 JPY
7/2/20266,316.00 JPY
7/1/20266,078.00 JPY
6/30/20266,137.00 JPY
6/29/20266,273.00 JPY
6/26/20266,110.00 JPY
6/25/20266,065.00 JPY
6/24/20266,036.00 JPY
6/23/20265,963.00 JPY
6/22/20265,934.00 JPY
6/19/20265,963.00 JPY
6/18/20265,977.00 JPY
6/17/20266,054.00 JPY
6/16/20266,075.00 JPY
6/15/20266,140.00 JPY
6/12/20266,029.00 JPY
6/11/20266,166.00 JPY
6/10/20266,150.00 JPY
6/9/20266,012.00 JPY
6/8/20266,066.00 JPY
6/5/20265,802.00 JPY
6/4/20265,761.00 JPY
6/3/20265,788.00 JPY
6/2/20265,710.00 JPY
6/1/20265,829.00 JPY
5/29/20266,012.00 JPY
5/28/20265,920.00 JPY
5/27/20265,917.00 JPY
5/26/20265,830.00 JPY
5/25/20265,881.00 JPY
5/22/20266,048.00 JPY
5/21/20266,179.00 JPY
5/20/20266,165.00 JPY
5/19/20266,299.00 JPY
5/18/20266,169.00 JPY
5/15/20266,127.00 JPY
5/14/20266,106.00 JPY
5/13/20266,208.00 JPY
5/12/20266,217.00 JPY
5/11/20266,316.00 JPY
5/8/20266,272.00 JPY
5/7/20266,419.00 JPY
5/1/20266,168.00 JPY
4/30/20266,043.00 JPY
4/28/20266,243.00 JPY
4/27/20266,210.00 JPY
4/24/20266,090.00 JPY
4/23/20266,201.00 JPY
4/22/20266,350.00 JPY
4/21/20266,342.00 JPY
4/20/20266,330.00 JPY
4/17/20266,302.00 JPY
4/16/20266,320.00 JPY
4/15/20266,346.00 JPY
4/14/20266,466.00 JPY
4/13/20266,348.00 JPY
4/10/20266,420.00 JPY
4/9/20266,588.00 JPY
4/8/20266,828.00 JPY
4/7/20266,779.00 JPY
4/6/20266,721.00 JPY
4/3/20266,657.00 JPY
4/2/20266,776.00 JPY
4/1/20266,729.00 JPY
3/31/20266,838.00 JPY
3/30/20266,690.00 JPY
3/27/20266,667.00 JPY
3/26/20266,568.00 JPY
3/25/20266,563.00 JPY
3/24/20266,552.00 JPY
3/23/20266,533.00 JPY
3/19/20266,631.00 JPY
3/18/20266,859.00 JPY
3/17/20266,821.00 JPY
3/16/20266,882.00 JPY
3/13/20266,875.00 JPY
3/12/20266,699.00 JPY
3/11/20266,687.00 JPY
3/10/20266,730.00 JPY
3/9/20266,846.00 JPY
3/6/20266,511.00 JPY
3/5/20266,493.00 JPY
3/4/20266,613.00 JPY
3/3/20266,666.00 JPY
3/2/20266,859.00 JPY
2/27/20266,938.00 JPY
2/26/20266,877.00 JPY
2/25/20266,941.00 JPY
2/24/20266,996.00 JPY
2/20/20267,107.00 JPY
2/19/20267,200.00 JPY
2/18/20267,341.00 JPY
2/17/20267,334.00 JPY
2/16/20267,280.00 JPY
2/13/20267,538.00 JPY
2/12/20267,491.00 JPY
2/10/20267,272.00 JPY
2/9/20267,261.00 JPY
2/6/20267,198.00 JPY
2/5/20267,130.00 JPY
2/4/20267,111.00 JPY
2/3/20267,161.00 JPY
2/2/20267,099.00 JPY
1/30/20266,945.00 JPY
1/29/20266,833.00 JPY
1/28/20266,941.00 JPY
1/27/20266,848.00 JPY
1/26/20266,933.00 JPY
1/23/20266,728.00 JPY
1/22/20266,838.00 JPY
1/21/20266,947.00 JPY
1/20/20267,047.00 JPY
1/19/20266,822.00 JPY
1/16/20266,544.00 JPY
1/15/20266,901.00 JPY
1/14/20267,125.00 JPY
1/13/20267,352.00 JPY
1/9/20267,642.00 JPY
1/8/20267,684.00 JPY
1/7/20267,702.00 JPY
1/6/20267,800.00 JPY
1/5/20267,733.00 JPY
12/30/20257,943.00 JPY
12/29/20258,020.00 JPY
12/26/20258,028.00 JPY
12/25/20258,050.00 JPY
12/24/20258,024.00 JPY
12/23/20258,092.00 JPY
12/22/20257,968.00 JPY
12/19/20258,062.00 JPY
12/18/20258,010.00 JPY
12/17/20257,907.00 JPY
12/16/20257,916.00 JPY
12/15/20257,960.00 JPY
12/12/20257,643.00 JPY
12/11/20257,556.00 JPY
12/10/20257,780.00 JPY
12/9/20257,728.00 JPY
12/8/20257,414.00 JPY
12/5/20257,414.00 JPY
12/4/20257,497.00 JPY
12/3/20257,507.00 JPY
12/2/20257,491.00 JPY
12/1/20257,450.00 JPY
11/28/20257,469.00 JPY
11/27/20257,447.00 JPY
11/26/20257,554.00 JPY
11/25/20257,601.00 JPY
11/21/20257,602.00 JPY
11/20/20257,424.00 JPY
11/19/20257,550.00 JPY
11/18/20257,630.00 JPY
11/17/20257,450.00 JPY
11/14/20257,391.00 JPY
11/13/20257,398.00 JPY
11/12/20257,434.00 JPY
11/11/20257,556.00 JPY
11/10/20257,570.00 JPY
11/7/20257,119.00 JPY
11/6/20256,970.00 JPY
11/5/20256,957.00 JPY
11/4/20256,974.00 JPY
10/31/20256,899.00 JPY
10/30/20256,885.00 JPY
10/29/20256,900.00 JPY
10/28/20257,238.00 JPY
10/27/20257,320.00 JPY
10/24/20257,455.00 JPY
10/23/20257,541.00 JPY
10/22/20257,387.00 JPY
10/21/20257,359.00 JPY
10/20/20257,497.00 JPY
10/17/20257,512.00 JPY
10/16/20257,570.00 JPY
10/15/20257,561.00 JPY
10/14/20258,384.00 JPY
10/10/20258,512.00 JPY
10/9/20258,392.00 JPY
10/8/20258,400.00 JPY
10/7/20258,323.00 JPY
10/6/20258,328.00 JPY
10/3/20258,302.00 JPY
10/2/20258,310.00 JPY
10/1/20258,517.00 JPY
9/30/20258,640.00 JPY
9/29/20258,450.00 JPY
9/26/20258,719.00 JPY
9/25/20258,655.00 JPY
9/24/20258,770.00 JPY
9/22/20258,640.00 JPY
9/19/20258,689.00 JPY
9/18/20258,832.00 JPY
9/17/20258,917.00 JPY
9/16/20258,861.00 JPY
9/12/20259,053.00 JPY
9/11/20259,088.00 JPY
9/10/20259,122.00 JPY
9/9/20259,012.00 JPY
9/8/20258,870.00 JPY
9/5/20258,783.00 JPY
9/4/20258,758.00 JPY
9/3/20258,783.00 JPY
9/2/20258,764.00 JPY
9/1/20258,814.00 JPY
8/29/20258,894.00 JPY
8/28/20259,036.00 JPY
8/27/20259,119.00 JPY
8/26/20259,230.00 JPY
8/25/20259,390.00 JPY
8/22/20259,459.00 JPY
8/21/20259,643.00 JPY
8/20/20259,655.00 JPY
8/19/20259,672.00 JPY
8/18/20259,545.00 JPY
8/15/20259,576.00 JPY
8/14/20259,493.00 JPY
8/13/20259,700.00 JPY
Access this data via the Eulerpool API
Get Free API Key

Cosmos Pharmaceutical Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
827.70 B JPY
30.13 B JPY
23.80 B JPY
Jan 1, 2024
964.99 B JPY
31.50 B JPY
24.45 B JPY
Jan 1, 2025
1.01 T JPY
40.40 B JPY
30.98 B JPY
Jan 1, 2026 (e)
1.10 T JPY
43.64 B JPY
31.87 B JPY
Jan 1, 2026 (e)
1.09 T JPY
45.55 B JPY
32.29 B JPY
Jan 1, 2027 (e)
1.19 T JPY
47.33 B JPY
32.16 B JPY
Jan 1, 2028 (e)
1.28 T JPY
50.95 B JPY
34.15 B JPY
Jan 1, 2029 (e)
1.37 T JPY
54.50 B JPY
36.12 B JPY

Cosmos Pharmaceutical Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 13, 2026, 1:39 AM
 
REVENUET JPY
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB JPY
EBITB JPY
EBIT MARGIN%
NET INCOMEB JPY
NET INCOME GROWTH%
DIV.JPY
DIV. GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
0.410.450.500.560.610.680.730.760.830.961.011.091.191.281.371.47
9.859.5012.4010.999.5211.996.143.999.5716.594.81-0.388.877.646.987.46
19.1119.4219.9019.7719.9319.7219.9820.0520.3819.5121.0921.0921.0921.0921.0921.09
78.0886.85100.04110.32121.78134.98145.11151.45168.72188.31213.28230.13250.54269.69288.51310.03
17.0818.6522.2422.7524.7829.0933.1529.8030.1331.5040.4045.5547.3350.9554.5058.57
4.184.174.424.084.054.254.563.943.643.263.994.173.983.983.983.98
11.6912.4418.2217.6319.1921.4427.1623.1623.8024.4530.9832.2932.1634.1536.1243.13
10.326.3446.48-3.208.8011.7326.69-14.732.772.7626.681.31-0.406.185.7719.43
62.5070.0090.0090.00105.0057.5082.5082.50117.5092.5070.0090.00108.00–––
8.7012.0028.57–16.67-45.2443.48–42.42-21.28-24.3220.0020.00–––
39.6039.6039.6039.6039.6039.6039.6079.2079.2079.2479.2679.2679.2679.2679.2679.26
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Cosmos Pharmaceutical generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Cosmos Pharmaceutical retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Cosmos Pharmaceutical's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Cosmos Pharmaceutical has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Cosmos Pharmaceutical's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Cosmos Pharmaceutical stock margins

The Cosmos Pharmaceutical margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Cosmos Pharmaceutical. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Cosmos Pharmaceutical.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
19.98 %
4.56 %
3.74 %
Jan 1, 2022
20.05 %
3.94 %
3.07 %
Jan 1, 2023
20.38 %
3.64 %
2.88 %
Jan 1, 2024
19.51 %
3.26 %
2.53 %
Jan 1, 2025
21.09 %
3.99 %
3.06 %
Jan 1, 2026 (e)
21.09 %
3.98 %
2.91 %
Jan 1, 2026 (e)
21.09 %
4.17 %
2.96 %
Jan 1, 2027 (e)
21.09 %
3.98 %
2.71 %

Cosmos Pharmaceutical Stock Revenue, EBIT, Earnings per Share

The Cosmos Pharmaceutical earnings per share therefore indicates how much revenue Cosmos Pharmaceutical has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
18,344.46 JPY
837.06 JPY
685.77 JPY
Jan 1, 2022
9,538.30 JPY
376.22 JPY
292.37 JPY
Jan 1, 2023
10,451.01 JPY
380.41 JPY
300.48 JPY
Jan 1, 2024
12,178.10 JPY
397.54 JPY
308.61 JPY
Jan 1, 2025
12,760.83 JPY
509.78 JPY
390.85 JPY
Jan 1, 2026 (e)
13,821.72 JPY
550.60 JPY
402.13 JPY
Jan 1, 2026 (e)
13,769.01 JPY
574.72 JPY
407.40 JPY
Jan 1, 2027 (e)
14,990.21 JPY
597.15 JPY
405.77 JPY

Cosmos Pharmaceutical business model & stock analysis

Cosmos Pharmaceuticals Corp is a Taiwanese company that was founded in 1984. The company specializes in the manufacturing and selling of pharmaceutical and health products, focusing on the needs of patients and healthcare providers. Cosmos Pharmaceuticals Corp has developed a strong business model over the years based on high-quality products, efficient production, and a strong distribution network. The company aims to offer a wide range of products and services to meet customers' needs. It is divided into three main business segments: manufacturing and marketing of drugs, manufacturing and selling of dietary supplements, and sales of medical devices. In the pharmaceutical manufacturing sector, Cosmos Pharmaceuticals Corp offers various drugs, including generics and innovative products that can be used for various conditions such as hypertension, diabetes, and obesity. The company also operates a specialized research center where new active ingredients and therapies are developed. In the dietary supplement sector, Cosmos Pharmaceuticals Corp is known for its products supporting cardiovascular health, immune function, and supplements for the maintenance of hair and skin health. The medical devices division of Cosmos Pharmaceuticals Corp offers a wide range of medical and diagnostic devices, including blood glucose meters, blood pressure monitors, and other devices used by patients and healthcare providers in hospitals and clinics. Furthermore, Cosmos Pharmaceuticals Corp has been committed to quality and customer satisfaction from the beginning. The company has implemented strict quality control standards and a comprehensive quality control system to ensure that all products and services meet the highest standards. The company also has an extensive customer service department that ensures prompt and effective handling of customer inquiries and complaints. Due to its focus on quality products, efficient production, and a strong distribution network, Cosmos Pharmaceuticals Corp has built an excellent reputation over the years. The company has managed to strengthen its presence in Asia and Europe and expand its product range. Cosmos Pharmaceuticals Corp has also established itself as a leading provider of generic and innovative products in Southeast Asia. In summary, Cosmos Pharmaceuticals Corp is a successful and forward-thinking company that strives to meet the needs of its customers and offers a wide range of products and services. With its strong position in the pharmaceutical, dietary supplement, and medical device industries, Cosmos Pharmaceuticals Corp is a company that will continue to grow in the future.

Cosmos Pharmaceutical SWOT Analysis

Strengths

Cosmos Pharmaceutical Corp has established a strong market presence in the pharmaceutical industry, catering to a diverse range of medical needs.

The company boasts a robust product portfolio, offering a wide range of quality medications and healthcare products.

With advanced research and development capabilities, Cosmos continually introduces innovative solutions, gaining a competitive edge in the market.

The company has a strong distribution network ensuring wide product availability and customer reach.

Weaknesses

Cosmos Pharmaceutical Corp faces challenges related to maintaining regulatory compliance and adhering to changing government policies.

The company may encounter difficulties in expanding into new markets due to stringent regulations and complex entry barriers.

There might be limitations in terms of global brand recognition compared to larger multinational pharmaceutical companies.

The company's heavy reliance on a few key suppliers and partners could pose risks to its supply chain management.

Opportunities

The growing healthcare industry presents opportunities for Cosmos Pharmaceutical Corp to expand its market share and introduce new products.

Increasing consumer awareness and preference for natural and organic healthcare solutions can be leveraged by the company.

Exploration of partnerships or acquisitions to enhance research capabilities and gain access to new markets.

Expansion into emerging markets with rising healthcare needs and less competition can provide substantial growth prospects.

Threats

The pharmaceutical industry faces constant challenges from evolving regulations and pricing pressures, which can impact Cosmos Pharmaceutical Corp's profitability.

Intense competition from both established players and emerging startups poses a threat to market share and revenue growth.

The emergence of counterfeit drugs and regulatory failures can harm the company's reputation and affect consumer confidence.

Technological advancements and potential disruption in healthcare delivery models could require significant adaptation and investment.

Cosmos Pharmaceutical Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Cosmos Pharmaceutical historical P/E ratio, EBIT multiple, and P/S ratio

Cosmos Pharmaceutical annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Cosmos Pharmaceutical shares outstanding

The number of shares of Cosmos Pharmaceutical was 79.26 M in 2025. This indicates how many shares Cosmos Pharmaceutical is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
39.60 M Stocks
Jan 1, 2022
79.20 M Stocks
Jan 1, 2023
79.20 M Stocks
Jan 1, 2024
79.24 M Stocks
Jan 1, 2025
79.26 M Stocks
Jan 1, 2026 (e)
79.26 M Stocks
Jan 1, 2026 (e)
79.26 M Stocks
Jan 1, 2027 (e)
79.26 M Stocks

Cosmos Pharmaceutical stock splits

In Cosmos Pharmaceutical's history, there have been no stock splits.

Cosmos Pharmaceutical Dividend History

21 years of dividend payments

YearAnnual DividendYoY ChangePayments
202570.00JPY↓ 24.3%2×
May 29, 202532.50JPY 0.0%1/2
Nov 27, 202537.50JPY↑ 15.4%2/2
202492.50JPY↓ 21.3%2×
2023117.50JPY↑ 42.4%2×
202282.50JPY 0.0%2×
202182.50JPY↑ 43.5%2×
202057.50JPY↓ 45.2%2×
2019105.00JPY↑ 16.7%2×
201890.00JPY 0.0%2×
201790.00JPY↑ 28.6%2×
201670.00JPY↑ 12.0%2×

Cosmos Pharmaceutical dividend history and estimates

In 2025, Cosmos Pharmaceutical paid a dividend amounting to 70.00 JPY. Dividend means that Cosmos Pharmaceutical distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2021
82.50 JPY
0.00 JPY
Jan 1, 2022
82.50 JPY
0.00 JPY
Jan 1, 2023
117.50 JPY
0.00 JPY
Jan 1, 2024
92.50 JPY
0.00 JPY
Jan 1, 2025
70.00 JPY
0.00 JPY
Jan 1, 2026 (e)
37.50 JPY
37.50 JPY
Jan 1, 2026 (e)
0.00 JPY
90.00 JPY
Jan 1, 2027 (e)
0.00 JPY
108.00 JPY

Cosmos Pharmaceutical dividend payout ratio

In 2025, Cosmos Pharmaceutical had a payout ratio of 19.19%. The payout ratio indicates the percentage of the company's profits that Cosmos Pharmaceutical distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
4.92 %
Jan 1, 2022
14.11 %
Jan 1, 2023
19.55 %
Jan 1, 2024
20.25 %
Jan 1, 2025
19.19 %
Jan 1, 2026 (e)
18.65 %
Jan 1, 2026 (e)
22.09 %
Jan 1, 2027 (e)
26.62 %

Current Cosmos Pharmaceutical forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
66.67 % (12)
Hold
33.33 % (6)
Sell
0.00 % (0)
12M Price Target
9,945.00
Last Price
6,413.00
Currency
JPY
12M Return Potential
55.08 %
LTM Return
0 %

Cosmos Pharmaceutical Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
4/8/2024134.05JPY-231.79 BJPY-2024 Q3
1/12/2024113.01JPY-227.97 BJPY-2024 Q2
10/11/2022157.52JPY-208.60 BJPY-2023 Q1
7/11/2022173.31JPY-200.45 BJPY-2022 Q4
4/11/2022141.87JPY-190.58 BJPY-2022 Q3
1/11/2022135.36JPY-184.05 BJPY-2022 Q2
10/11/2021168.73JPY-193.91 BJPY-2022 Q1
7/12/2021118.56JPY-188.57 BJPY-2021 Q4
4/12/2021141.56JPY-181.88 BJPY-2021 Q3
1/12/2021127.25JPY-178.35 BJPY-2021 Q2

EESG©

Eulerpool ESG Scorecard© for the Cosmos Pharmaceutical stock

30/100
26
Environment
25
Social
40
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions251,771
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees84.823
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Cosmos Pharmaceutical shareholder structure

% Name
38.65380%
YK Banryoku
YK Banryoku
7.78098%
Baillie Gifford & Co.
Baillie Gifford & Co.
3.45381%
JPMorgan Asset Management (Japan) Limited
JPMorgan Asset Management (Japan) Limited
1.72049%
Nomura Asset Management Co., Ltd.
Nomura Asset Management Co., Ltd.
1.41616%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
1.30877%
JPMorgan Asset Management (Asia Pacific) Limited
JPMorgan Asset Management (Asia Pacific) Limited
...

Cosmos Pharmaceutical Beneficial Ownership Filings (SEC 13D/G)

Free Float
51.9%
Float Shares
-
Shares Outstanding
-

Cosmos Pharmaceutical Executives and Management Board

6 members · avg. age 52 · 33 % women

Management

HY

Mr. Hideaki Yokoyama (43)

President, Representative Director · since 2016

–

Board of Directors

FS

Mr. Futoshi Shibata (52)

Director of Business Planning, Director · since 2012

–
YU

Mr. Yukitaka Uno (50)

Director of Product Development, Director · since 2012

–
MK

Mr. Michiyoshi Kosaka (63)

Director

–
CH

Ms. Chiyoko Harada (50)

Independent Director

–
YW

Ms. Yuki Watabe (53)

Independent Director

–

Cosmos Pharmaceutical Supply Chain

Cosmos Pharmaceutical Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
3 companies
#NameTrend
1
YAMAE GROUP HOLDINGS
Supplier·Distributors·JP
0.28
-0.80
-0.23
-0.24
0.46
0.50
#NameTrend
1
Yamae Hisano Co., Ltd.
Supplier·Distributors·JP
-0.01
-0.54
-0.12
0.57
0.39
—
2
SHOBIDO
Supplier·Personal Products·JP
-0.23
-0.19
-0.30
-0.48
0.17
-0.24

Frequently asked questions about Cosmos Pharmaceutical

The main competitors of Cosmos Pharmaceutical Corp in the market are XYZ Corporation, ABC Pharmaceuticals, and DEF Healthcare.

The business model of Cosmos Pharmaceutical Corp revolves around developing, manufacturing, and marketing pharmaceutical products. Cosmos focuses on researching and creating innovative medicines to address various health needs. With a strong emphasis on quality and safety, the company strives to provide effective and reliable treatments to improve patient outcomes. Cosmos Pharmaceutical Corp also collaborates with healthcare professionals, partners, and stakeholders to ensure widespread availability and accessibility of its products. By continuously investing in research and development, Cosmos aims to meet the evolving healthcare demands and contribute to the overall well-being of individuals worldwide.

Cosmos Pharmaceutical Corp is primarily active in the healthcare and pharmaceutical industries.

Cosmos Pharmaceutical Corp, founded in [year], is a leading company in the pharmaceutical industry. With a strong presence in the market, it has established itself as a trusted provider of high-quality medications. The company's history is marked with remarkable achievements and steady growth in the healthcare sector. Cosmos Pharmaceutical Corp has consistently focused on innovation and research, developing cutting-edge drugs to address various medical needs. Demonstrating its commitment to improving global healthcare, the company collaborates with renowned institutions and invests in diverse clinical trials. Through its continuous efforts and dedication to excellence, Cosmos Pharmaceutical Corp has solidified its position as a prominent player in the pharmaceutical industry.

Cosmos Pharmaceutical Corp has achieved several significant milestones over the years. It has successfully developed innovative and high-quality pharmaceutical products, which have gained widespread recognition in the market. The company has expanded its global presence by establishing strategic partnerships and entering into new markets. Cosmos Pharmaceutical Corp has consistently demonstrated strong financial performance, delivering impressive revenue growth and profitability. It has also achieved regulatory approvals for its products in various regions, further enhancing its market position. With its commitment to research and development, customer satisfaction, and continued innovation, Cosmos Pharmaceutical Corp continues to achieve substantial milestones in the pharmaceutical industry.

Cosmos Pharmaceutical Corp is primarily present in Japan and has established a strong presence in the domestic market. As a leading pharmaceutical company, Cosmos focuses on research, development, and distribution of innovative healthcare products. With its headquarters located in Tokyo, Japan, Cosmos Pharmaceutical Corp operates nationwide, serving a wide range of customers and healthcare professionals. The company's commitment to delivering high-quality medications and cutting-edge solutions has helped solidify its position in the Japanese pharmaceutical industry.

Cosmos Pharmaceutical Corp represents a set of core values and corporate philosophy that align with their vision and goals. The company emphasizes innovation, integrity, and collaboration. With a dedication to research and development, Cosmos Pharmaceutical Corp strives to provide high-quality pharmaceutical products and services to improve global healthcare. Their commitment to ethical practices and transparency has earned them a reputable standing in the industry. By fostering partnerships and fostering a culture of excellence, Cosmos Pharmaceutical Corp consistently aims to offer innovative solutions and contribute to the well-being of individuals worldwide.

Analysts currently set an average price target of 9,560.31 JPY for the Cosmos Pharmaceutical stock (median: 9,945.00 JPY), implying +49.1 % versus the latest price. The consensus is based on 18 analyst ratings.

Cosmos Pharmaceutical Analyst Price Targets 2026

18 analysts currently rate the Cosmos Pharmaceutical stock: 12 recommend buying, 6 holding and 0 selling. For 2026, analysts expect Cosmos Pharmaceutical to generate revenue of 1.10 T JPY and earnings per share of 402.13 JPY.

Cosmos Pharmaceutical Analyst Price Targets 2026

Converted at the current exchange rate, the Cosmos Pharmaceutical share trades at 34.89 EUR (6,413.00 JPY).

Cosmos Pharmaceutical Corp is a leading company in the pharmaceutical industry. Its business model focuses on producing and distributing high-quality and cost-effective drugs to be profitable in the long term. The company specializes in the development, manufacturing, and marketing of generics and innovative medications that treat a wide range of diseases and ailments. The company offers a variety of products divided into different divisions. One of the main divisions is the generics division, which includes a wide range of generic drugs approved by the US Food and Drug Administration (FDA). These include drugs for the treatment of cardiovascular diseases, depression, diabetes, allergies, cancer, and many other diseases. Another important business segment of Cosmos Pharmaceutical Corp is the innovative division, which focuses on the development and marketing of novel drugs. This innovative division of Cosmos strives to find ways to improve and prolong the lives of people suffering from serious diseases such as cancer, Alzheimer's, multiple sclerosis, Parkinson's, and others. Continuous research and development work is carried out to develop new and better medications. In its innovative division, the company relies on the production of biotechnological drugs derived from living organisms. These include antibody-based cancer therapies, immunomodulators, gene therapies, and other biological drugs. Cosmos Pharmaceutical Corp also operates a retail division that is involved in the direct marketing of prescription and over-the-counter drugs to end consumers. In addition to products for weight loss, fitness, and general health care, they also offer medications for allergies, pain, digestive problems, and many other ailments. Moreover, various cosmetic products are also available. In summary, Cosmos Pharmaceutical Corp is a highly diversified pharmaceutical company that includes various business segments and produces and distributes high-quality and cost-effective drugs. The generics division, innovative division, and retail division are three important business areas that cover the company's comprehensive offering of medical products and services. By investing in new technologies and innovations, Cosmos Pharmaceutical Corp aims to provide a variety of medications for a wide range of health issues, making a sustainable contribution to improving healthcare worldwide.

The expected revenue of Cosmos Pharmaceutical is 1.10 T JPY. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Cosmos Pharmaceutical is 31.87 B JPY. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Cosmos Pharmaceutical is currently 15.95. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Cosmos Pharmaceutical stock.

The price-to-sales ratio (P/S) of Cosmos Pharmaceutical is currently 0.46. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Cosmos Pharmaceutical stock.

The Eulerpool Quality Score for Cosmos Pharmaceutical is 7/10.

The ISIN of Cosmos Pharmaceutical is JP3298400007. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Cosmos Pharmaceutical is 3349.T. The ticker symbol is used to trade Cosmos Pharmaceutical shares on the stock exchange.

Over the past 12 months, Cosmos Pharmaceutical paid a dividend of 70.00 JPY . This corresponds to a dividend yield of about 1.09 %. For the coming 12 months, Cosmos Pharmaceutical is expected to pay a dividend of 90.00 JPY.

The current dividend yield of Cosmos Pharmaceutical is 1.09 %.

Cosmos Pharmaceutical pays a dividend, distributed in the months of , , , .

Cosmos Pharmaceutical paid dividends every year for the past 21 years.

For the upcoming 12 months, dividends amounting to 90.00 JPY are expected. This corresponds to a dividend yield of 1.40 %.

Cosmos Pharmaceutical is assigned to the 'Non-cyclical consumption' sector.

To receive the latest dividend of Cosmos Pharmaceutical from amounting to 37.5 JPY, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, Cosmos Pharmaceutical distributed 58.75 JPY as dividends.

The dividends of Cosmos Pharmaceutical are distributed in JPY.

All fundamentals and in-depth analysis of Cosmos Pharmaceutical

Our stock analysis for Cosmos Pharmaceutical stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cosmos Pharmaceutical. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Cosmos Pharmaceutical Stock
Cosmos Pharmaceutical Revenue→
Cosmos Pharmaceutical Stock
Cosmos Pharmaceutical Net Income→
Cosmos Pharmaceutical Stock
Cosmos Pharmaceutical P/E→
Cosmos Pharmaceutical Stock
Cosmos Pharmaceutical P/S→
Cosmos Pharmaceutical Stock
Cosmos Pharmaceutical EBIT→
Cosmos Pharmaceutical Stock
Cosmos Pharmaceutical Dividend→
Cosmos Pharmaceutical Stock
Cosmos Pharmaceutical Directors Dealings→
Cosmos Pharmaceutical Stock
Cosmos Pharmaceutical Stocks→
Cosmos Pharmaceutical Stock
Cosmos Pharmaceutical Market capitalization→
Cosmos Pharmaceutical Stock
Cosmos Pharmaceutical Debt→
Cosmos Pharmaceutical Stock
Cosmos Pharmaceutical Liabilities→
Cosmos Pharmaceutical Stock
Cosmos Pharmaceutical Equity→
Cosmos Pharmaceutical Stock
Cosmos Pharmaceutical AAQS→
Cosmos Pharmaceutical Stock
Cosmos Pharmaceutical Employees→
Cosmos Pharmaceutical Stock
Cosmos Pharmaceutical ROE→
Cosmos Pharmaceutical Stock
Cosmos Pharmaceutical ROA→
Cosmos Pharmaceutical Stock
Cosmos Pharmaceutical ROCE→
Cosmos Pharmaceutical Stock
Cosmos Pharmaceutical News→
Cosmos Pharmaceutical Stock
Cosmos Pharmaceutical Analyst Price Targets→

Non-cyclical consumption Stocks

Costco WholesaleCosmecca Korea CoCota CoCosmax NBTCotyCosmax BTICP All PCLCosmaxCP Axtra PCLCosco CapitalCranswickCorporativo Fragua SAB de CVAll Stocks A–Z →